Novavax, Inc. Expected to Earn FY2025 Earnings of $1.87 Per Share (NASDAQ:NVAX)

Novavax, Inc. (NASDAQ:NVAX – Get Rating) – Analysts at Zacks Research issued their FY2025 earnings per share estimates for Novavax in a report released on Wednesday, March 15th. Zacks Research analyst S. Ganoria expects that the biopharmaceutical company will post earnings per share of $1.87 for the year. The consensus estimate for Novavax’s current full-year earnings is ($5.00) per share.

Novavax (NASDAQ:NVAX – Get Rating) last posted its quarterly earnings data on Tuesday, February 28th. The biopharmaceutical company reported ($2.28) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($1.36). The firm had revenue of $357.40 million during the quarter, compared to analysts’ expectations of $383.14 million. During the same quarter in the prior year, the firm posted ($11.18) earnings per share. The firm’s quarterly revenue was up 60.8% on a year-over-year basis.

A number of other research analysts have also recently weighed in on NVAX. B. Riley cut Novavax from a “buy” rating to a “neutral” rating in a research report on Wednesday, March 1st. StockNews.com started coverage on Novavax in a report on Thursday. They issued a “sell” rating on the stock. HC Wainwright reissued a “buy” rating and issued a $110.00 price target on shares of Novavax in a report on Monday, February 13th. Finally, Jefferies Financial Group started coverage on Novavax in a report on Friday, December 2nd. They issued a “hold” rating on the stock. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $76.29.

Novavax Stock Down 0.3 %

NVAX stock opened at $5.95 on Friday. Novavax has a twelve month low of $5.68 and a twelve month high of $85.60. The stock has a market cap of $512.73 million, a P/E ratio of -0.71 and a beta of 1.78. The business’s 50-day moving average price is $9.74 and its 200-day moving average price is $16.26.

Institutional Trading of Novavax

Large investors have recently added to or reduced their stakes in the company. Neo Ivy Capital Management bought a new stake in Novavax in the 3rd quarter worth approximately $37,000. Money Concepts Capital Corp bought a new stake in Novavax in the 4th quarter worth approximately $37,000. CI Investments Inc. increased its stake in Novavax by 1,572.8% in the 4th quarter. CI Investments Inc. now owns 3,747 shares of the biopharmaceutical company’s stock worth $39,000 after acquiring an additional 3,523 shares during the last quarter. Credit Agricole S A increased its stake in Novavax by 65.8% in the 3rd quarter. Credit Agricole S A now owns 2,520 shares of the biopharmaceutical company’s stock worth $46,000 after acquiring an additional 1,000 shares during the last quarter. Finally, IFP Advisors Inc increased its stake in Novavax by 328.3% in the 4th quarter. IFP Advisors Inc now owns 6,994 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 5,361 shares during the last quarter. Institutional investors own 45.70% of the company’s stock.

Novavax Company Profile

(Get Rating)

Novavax, Inc Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.